Key Takeaways
- Pharma drives a strong quarter: Revenue grew 29% YoY to ₹453 crores, with EBITDA up 30%, powered by API volume offtake and a 934 bps YoY jump in Pharma EBIT margin.
- Crop Protection is a tale of two metrics: Volume grew 22% but value degrew ~4% because pricing pressure forced higher volumes to be sold at lower realizations.
- CDMO is becoming the core Pharma story: The CDMO share of Pharma revenue rose to close to 40%, up over 10% as a share of total revenue, with two NCEs in Phase 3 trials and commercial supplies expected in H2 CY25.
- New assets are a near-term drag, long-term lever: A combined ₹8.9 crores in finance costs and depreciation from recent additions weighed on profit, a headwind that fades as production ramps.
- What to watch next quarter: Whether the Q3 seasonal slowdown in Pharma shipments materializes as flagged, the pace of Crop Protection margin recovery as capacity utilization rises from 55–60%, and any concrete update on the two Phase 3 NCEs.
Pharma: The Quarter's Engine
- Broad-based volume growth: API volume offtake improved materially on the back of successful customer acquisition globally, while CDMO validation quantities were supplied for an innovator customer.
- Margin surge: Pharma EBIT margin expanded 934 bps YoY and 994 bps QoQ, driven by a mix shift toward higher-margin, higher-value products: value grew 9% on just 3.5% volume growth.
- Pipeline depth: Eight to nine products in the development pipeline, with a cadence of two to three new product introductions each year. Two DMFs for anti-coagulant products were filed for the US and Europe markets in Q2.
- CDMO project maturity: Projects are typically in Phase 2, 2A, 2B and moving into Phase 3; volumes ramp up within 1–2 years and then get launched. Two projects for new chemical entities are making strong progress in Phase 3 clinical trials, with ramp-up expected in 2026–2027.
- Customer engagement rising: Customer audits increased at least 50% versus last year, from all geographies including the US, Europe and Japan, a leading indicator of future business.
Sameer Hiremath: "quarter 3 is the financial year ending for many of our customers in both in pharma and in crop... the orders are all in place in the system, but they ask us to ship in January onwards. They don't want to take any shipments in December."
Crop Protection: Volume Up, Price Down
- The divergence: Crop Protection volume grew 22% while value degrew ~4%, because higher volumes were sold at lower realizations under persistent market pricing pressure.
- Margin compressed by low operating leverage: EBIT margin fell to 5%, a direct consequence of capacity utilization running at only 55–60%, leaving over 40% of the gross block unutilized.
- Recovery thesis: Management stated the worst is behind and expects improvements to begin from H2 of FY26, if not H1, as capacity ramp-up restores operating leverage.
- Strategic pivot to on-patent chemistry: The company is shifting its Crop Protection focus toward new chemical entities and new-generation on-patent chemistry where Chinese competition is less prevalent, a defensive move against a competitor management calls a long-term serious threat.
Sameer Hiremath: "China is definitely a long-term serious competitor, and I don't think they're going away soon. So we have to compete and we're getting involved in crop protection more on the new chemical entities and the new generation on-patent chemistry, where China is not prevalent."
CDMO: The Structural Growth Story
- Revenue share rising: CDMO now accounts for close to 40% of Pharma revenue, up over 10% as a share of total company revenue, and management expects this proportion to increase further. Contract research is now negligible; all business has migrated to CDMO over the last 5–6 years.
- Near-term catalyst: Commercial supplies for an innovator customer are expected in the second half of calendar year 2025.
- NCE pipeline: Two novel NCEs in Phase 3 trials will be commercialized in the next 2–3 years, with a small portion of validation quantities supplied this year.
- Inquiry funnel healthy: Several CDMO inquiries received, with an increased share from early-stage molecules and advanced discussions moving toward development and validation.
- Crop CDMO pipeline: A robust pipeline of seven products from existing and potential clients is in place, with 2–3 projects closer to a 3–4 year commercialization timeline; the typical cycle is 3–6 years depending on the stage.
Animal Health & New Verticals
- Animal health facility validated: Six products successfully validated, with additional products undergoing validation to be completed over the next few quarters. Regulatory filings for commercial sales have been initiated.
- Commercialization timeline: The initial batch is going through the final stages of registration; commercial supply is expected over the next few quarters. Once the innovator customer's product portfolio validation finishes in the next 1–2 quarters, the company will begin validating other products in development.
- Specialized ingredients: Projects are progressing well and expected to reach peak revenue in the upcoming 2–3 years.
- GLP-1 evaluation: The company is evaluating GLP-1 inhibitors but has no firm plan yet.
Geographies & Competitive Positioning
- Japan as a growth vector: Japan is already a large part of total business and will grow quite substantially; customer relationships are in place for APIs and intermediates across both Pharma and Crop, and the number of inquiries from Japan is increasing.
- Onshoring sales expansion: The company is increasing its presence by placing two people in North America, hiring in Europe, strengthening its presence in Japan, and setting up an office in Latin America.
- BIOSECURE Act tailwind: US innovative customers are looking more toward India in the last year due to the BIOSECURE Act, a structural shift that benefits Indian CDMO players.
Sameer Hiremath: "Japan is already a large part of our total business, and it will grow quite substantially. And we've already got customer relationships already in play, whether it's for APIs or for intermediates on both the Pharma and on the crop side. And this is only increasing. The number of inquiries from Japan is increasing, and we stand to benefit from this. I see this very positively."
Balance Sheet & Capital Allocation
- Working capital improved: A reduction of ₹50 crores was driven by inventory control, production planning improvements, and just-in-time inflow for some products.
- Debt trajectory: Debt has come down over the six-month period; management described the position as very comfortable and does not see any significant increase. Debt is expected to be close to ₹800 crores for the current year, with ₹130 crores in repayments next year, keeping debt in the same range as capex borrowing continues.
- Capex focus: Capital expenditure is largely directed toward the Pharma business. New Pharma capacity is coming on stream next year, though it takes 1–2 years to commercialize.
- R&D commitment: The company continues to allocate approximately 4–5% of revenue to R&D.
- Project Pinnacle: A transformation initiative that is yielding positive outcomes.
Sameer Hiremath: "debt has actually come down for the 6 months... it's a very, very comfortable position, and we don't see any significant increase in this."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Pharma momentum | Expect same momentum to continue; Q3 may see suppressed growth but Q4 will bounce back; H2 overall in the same line | H2 FY25 |
| CDMO commercial supplies | Commercial supplies for an innovator customer | H2 CY25 |
| Animal health commercialization | Validated products submitted for registration, then final commercialization | Next few quarters |
| NCE commercialization | Two novel NCEs in Phase 3 trials | Next 2–3 years |
| Specialized ingredients peak revenue | Projects progressing well | Upcoming 2–3 years |
| Crop Protection margin improvement | Margin profile to improve as capacity ramp-up takes place | H2 FY26, if not H1 FY26 |
| Debt range | Debt expected close to ₹800 crores for current year; ₹130 crores repayment next year; range maintained with capex borrowing | FY25 / FY26 |
| R&D spend | Continue to allocate ~4–5% of revenue | Ongoing |
| H2 vs H1 | H2 expected to be stronger than H1 | FY25 |
| FY26 vs FY25 | Expect growth in both Pharma revenue and margins | FY26 |
| CDMO share of Pharma revenue | Expect CDMO percentage to increase further | Going forward |
| Animal health validation completion | Finish validation of innovator customer product portfolio, then start other products | Next 1–2 quarters |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Revenue | ₹453 cr, +29% QoQ and +29% YoY |
| EBITDA | ₹75 cr, +30% QoQ and +30% YoY |
| EBITDA margin | 16.5%, up from 13.2% in Q2 FY24 |
| H1 FY25 revenue | ₹860 cr, +4% QoQ and +23% YoY |
| H1 FY25 EBITDA | ₹133 cr |
| H1 FY25 EBITDA margin | 15.5% |
| Pharma revenue | ₹294 cr, EBIT ₹40 cr |
| Pharma EBIT margin change | +934 bps YoY and +994 bps QoQ |
| Pharma value growth | +9% (Q2), volume growth +3.5% |
| Pharma value growth (H1) | +6%, volume growth +5% |
| Crop Protection revenue | ₹159 cr, EBIT ₹8 cr, EBIT margin 5% |
| Crop Protection value growth | -4% (Q2), volume growth +22% |
| Crop Protection value growth (H1) | +2%, volume growth +45% |
| Pharma capacity utilization | 75%–80% |
| Crop Protection capacity utilization | 55%–60% |
| CDMO share of Pharma revenue | ~40%, up over 10 percentage points |
| Working capital reduction | ₹50 cr |
| Debt expected (FY25) | ~₹800 cr, with ₹130 cr repayment due in FY26 |
| R&D spend | ~4%–5% of revenue |
| Animal health products validated | 6 products, registrations expected in 12–18 months |
| Crop Protection CDMO pipeline | 7 projects, 2–3 closer to 3–4 year timeline |
| Customer audits | At least 50% above last year (rough estimate) |